Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: A retrospective study
Modern Rheumatology · 2024
DOI: 10.1093/mr/road078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Yasuhiro Hasegawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Remission Induction, Immunosuppressive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
We investigated the effect of belimumab (BEL) on achieving low disease activity (LDA) and remission as an additive molecular-targeting agent to standard of care (SoC) in patients with systemic lupus erythematosus (SLE).
Methods
Clinical information was retrospectively collected from patients with SLE who received BEL additive to SoC (BEL + SoC), and from patients treated with SoC alone as a control arm. Disease activity was measured by SLE-disease activity score (SLE-DAS). The proportion of patients in LDA and remission at 12 months was compared after propensity score matching. The factors contributing to LDA and remission achievement were identified by Cox proportional hazard model.
Results
BEL + SoC significantly reduced SLE-DAS at 6 months, with a significantly higher proportion of patients achieving LDA and remission at 12 months compared to SoC alone. The presence of arthritis at baseline was significantly associated with achieving LDA and remission. Additionally, both treatment groups experienced a significant reduction in daily glucocorticoid dose.
Conclusions
Adding BEL to SoC was beneficial for patients with arthritis, leading to higher proportion of achieving LDA and remission, while also reducing their glucocorticoid dose. Our results indicate the utility of BEL in a treat-to-target approach for SLE patients in a real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan.
ORCID-Profile: Yoshiyuki Arinuma, Kunihiro Yamaoka
Zitieren
APA
Hasegawa, Y., Arinuma, Y., Asakura, H., Shindo, R., Ino, K., Kanayama, Y., Tanaka, T., Matsueda, Y., Wada, T., Oku, K., & Yamaoka, K. (2024). Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: A retrospective study. Modern Rheumatology. https://doi.org/10.1093/mr/road078
Vancouver
Hasegawa Y, Arinuma Y, Asakura H, Shindo R, Ino K, Kanayama Y, et al. Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: A retrospective study. Modern Rheumatology. 2024. doi:10.1093/mr/road078
BibTeX
@article{Hasegawa2024,
author = {Hasegawa, Yasuhiro and Arinuma, Yoshiyuki and Asakura, Hirotomo and Shindo, Risa and Ino, Kazuma and Kanayama, Yoshiro and Tanaka, Tomoki and Matsueda, Yu and Wada, Tatsuhiko and Oku, Kenji and Yamaoka, Kunihiro},
title = {Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: A retrospective study},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/road078}
}
EUVIMED